目的 探讨京尼平苷对高脂肪/高果糖饮食诱导代谢综合征(HFFD-MS)大鼠的干预作用及对脂肪因子的影响。方法 高脂肪/高果糖饮食持续16周,构建大鼠HFFD-MS模型,随机分为模型组、京尼平苷三个剂量组(分别按30、60、120 mg/kg)、阳性对照组(二甲双胍50 mg/kg);另取同期给予普通饲料和纯水饲养的大鼠为正常组,每组10只。灌胃给药8周,计算脂体比及胰岛素抵抗模型评估指数(HOMA-IR),检测空腹血糖(FBG)及血清总胆固醇(TC)、三酰甘油(TG)、游离脂肪酸(FFA)及胰岛素(INS)水平,观察肾周脂肪细胞病理学改变,放射免疫法检测血清脂肪因子瘦素(LP)、内脂素(VIS)、脂联素(APN)、抵抗素(RES)、肿瘤坏死因子α(TNF-α)、白介素6( IL-6)的表达水平。结果 与模型组相比,京尼平苷各剂量组肾周脂肪细胞体积更小,排列更紧密;且可明显降低HFFD-MS大鼠的体质量、内脏脂肪质量及脂体比,差异有统计学意义(P<0.05)。另外,京尼平苷各剂量组可显著下调TC、TG、FFA、FBG、INS水平及HOMA-IR指数(P<0.01),可使血清LP、RES、TNF-α、IL-6水平明显降低(P<0.05),且京尼平苷高剂量组可显著上调APN的表达,差异有统计学意义(P<0.01),对VIS无显著性影响。结论 京尼平苷具有调控脂肪因子的异常分泌、减少内脏脂肪堆积、纠正糖脂代谢紊乱等作用,可明显改善HFFD-MS病理进程。
Abstract
Objective To explore the effect of geniposide on high fat/high fructose diet-induced metabolic syndrome (HFFD-MS) and its influence on the adipocytokines. Methods HFFD-MS models of rats were induced by a 16-week high-fat/high-fructose diet, and were randomly divided into model group, geniposide dose groups (30, 60 and 120 mg/kg, respectively), and positive control (metformin 50 mg/kg) group, while the other rats fed with ordinary diet and pure water in the same period were divided into normal group with 10 rats in each group. After 8 weeks of intragastric administration, the fat-body ratio and insulin resistance (HOMA-IR) were calculated, fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), free fatty acid (FFA), and insulin (INS) levels in serum were detected, and the pathologic changes were observed in perirenal adipocytes. The serum levels of adipocytokine leptin (LP), visfatin (VIS), adiponectin (APN), resistin (RES), tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6) were detected by radioimmunoassay. Results The perirenal adipocytes in geniposide dose groups were smaller and more tightly arranged than those in the model group. Compared with the model group, geniposide administration significantly reduced the body and visceral fat weights, and fat-body ratio in HFFD-MS rats (P<0.05), significantly down-regulated FBG, HOMA-IR and serum TC, TG, FFA and INS levels (P<0.01), significantly reduced serum LP, RES, TNF-α and IL-6 levels (P<0.05 or P<0.01), and the high-dose of geniposide evidently up-regulated the expression of APN (P<0.01). Geniposide administration had no significant effect on VIS. Conclusions Geniposide can obviously improve the pathological process of HFFD-MS by regulating the abnormal secretion of adipokines, reducing the accumulation of visceral fat and correcting the disorder of glucose-lipid metabolism.
关键词
京尼平苷 /
代谢综合征 /
大鼠 /
高脂肪/高果糖 /
脂肪因子
Key words
geniposide /
metabolic syndrome /
rat /
high fat/high fructose /
adipocytokine
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Zhou Y X, Zhang R Q, Rahman K, et al. Diverse pharmacological activities and potential medicinal benefits of geniposide[J]. Evid Based Complement Alternat Med, 2019,2019:4925682.
[2] 刘金鑫. 京尼平苷调控小鼠糖脂代谢的机理研究[D]. 无锡: 江南大学,2021.
[3] Gao S, Feng Q. The beneficial effects of geniposide on glucose and lipid metabolism: a review[J]. Drug Des Devel Ther, 2022,16:3365-3383.
[4] Moreno-Fernández S, Garcés-Rimón M, Vera G, et al. High fat/high glucose diet induces metabolic syndrome in an experimental rat model[J]. Nutrients, 2018, 10(10): 1502.
[5] Saeed S, Waje A U, Nilsson P M. The association of the metabolic syndrome with target organ damage: focus on the heart, brain, and central arteries[J]. Expert Rev Cardiovasc Ther, 2020,18(9):601-614.
[6] 中华医学会老年医学分会老年内分泌代谢疾病学组中国老年代谢综合征药物治疗专家共识(2022)编写组. 中国老年人代谢综合征药物治疗专家共识(2022)[J]. 中华老年医学杂志,2022,41(9):1011-1027.
[7] Ma Z G, Kong C Y, Song P, et al. Geniposide protects against obesity-related cardiac injury through AMPKα- and Sirt1-dependent mechanisms[J]. Oxid Med Cell Longev, 2018,2018:6053727.
[8] 张光辉.在代谢综合征疾病临床治疗中采用二甲双胍对血糖、血脂水平的影响[J].黑龙江中医药,2021,50(3):87-88.
[9] Ross R, Després J P. Abdominal obesity, insulin resistance, and the metabolic syndrome: contribution of physical activity/exercise[J]. Obesity (Silver Spring), 2009,17 (Suppl 3):S1-S2.
[10] 胡 伟, 尹春燕, 肖延风. 腹型肥胖对炎性因子及代谢综合征的影响[J]. 中国儿童保健杂志, 2015,23(3):287-289.
[11] Jiang B, Chen Y, Zhou K, et al. Comparison of abdominal obesity and fattyliver and their association with insulin resistance and metabolic syndrome in Chinese adults[J]. Obesity (Silver Spring), 2019,27(5):707-715.
[12] 李 伟, 曾一文, 王 婧, 等. 微小RNA-22对妊娠糖尿病患者糖代谢的影响[J]. 武警医学, 2023,34(2):93-96,103.
[13] Lei R, Chen S, Li W. Advances in the study of the correlation between insulin resistance and infertility[J]. Front Endocrinol (Lausanne), 2024,15:1288326.
[14] Xu S, Ren R, Li W, et al. The association between obesity indicators and metabolic risk factors in type-2 diabetic patients[J]. Heliyon, 2023,9(9):e20013.
[15] Li G, Robles S, Lu Z, et al. Upregulation of free fatty acid receptors in periodontal tissues of patients with metabolic syndrome and periodontitis[J]. J Periodontal Res, 2019,54(4): 356-363.
[16] Aisike G, Kuerbanjiang M, Muheyati D, et al. Correlation analysis of obesity phenotypes with leptin and adiponectin[J]. Sci Rep, 2023,13(1):17718.
[17] Ugur K, Erman F, Turkoglu S, et al. Asprosin, visfatin and subfatin as new biomarkers of obesity and metabolic syndrome[J]. Eur Rev Med Pharmacol Sci, 2022,26(6):2124-2133.
[18] Bajpai A. HOMA-AD and metabolic syndrome-the homecoming of adiponectin in pediatric obesity[J]. Indian J Pediatr, 2021,88(4):322-323.
[19] Primo D, Izaola O, Luis D. Resistin/uric acid index as a marker of metabolic syndrome in females with obesity[J]. Int J Obes (Lond), 2023,47(5):393-398.
[20] Mohammadi M, Gozashti M H, Aghadavood M, et al. Clinical significance of serum IL-6 and TNF-α levels in patients with metabolic syndrome[J]. Rep Biochem Mol Biol, 2017,6(1):74-79.
PDF(1335 KB)
